Ultragenyx Pharmaceutical INC Form 4 insider transactions

Ultragenyx Pharmaceutical Inc.'s EVP and Chief Medical Officer, Eric Crombez, reported the conversion of performance stock units and subsequent sale of shares for tax withholdings.

Ultragenyx Pharmaceutical Inc. EVP Dennis Karl Huang reported the conversion of performance stock units into 11,137 shares and the disposition of 999 shares for tax withholdings.

Ultragenyx Pharmaceutical's Chief Financial Officer, Howard Horn, sold 3,061 shares of common stock for $23.56 per share as part of a pre-arranged trading plan.

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, sold 3,150 shares of common stock for $22.84 per share in a pre-planned transaction.

Ultragenyx Pharmaceutical Inc.'s SVP, Chief Accounting Officer, Theodore Alan Huizenga, sold 85 shares of common stock to cover tax obligations related to RSU vesting.

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, sold 3,081 shares of common stock for $36.38 per share under a Rule 10b5-1 plan.

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, reported a planned sale of 7,942 shares of common stock at $31.51 per share to cover tax obligations from RSU vesting.

Ultragenyx Pharmaceutical Inc.'s SVP, Chief Accounting Officer, Theodore Alan Huizenga, sold 64 shares of common stock to cover tax withholdings from RSU vesting.

Ultragenyx Pharmaceutical's EVP and Chief Legal Officer, Karah Parschauer, reported the sale of 2,450 shares of common stock at $31.17 per share, executed under a Rule 10b5-1 plan.

Ultragenyx Pharmaceutical Inc.'s SVP, Chief Accounting Officer, Theodore Alan Huizenga, sold 84 shares of common stock to cover tax obligations related to RSU vesting.

Ultragenyx Pharmaceutical Inc. Director Corazon D. Sanders sold 2,405 shares of common stock for approximately $90,000 as part of a pre-scheduled Rule 10b5-1 trading plan.

Director Shehnaaz Suliman reports acquisition of restricted stock units and stock options in Ultragenyx Pharmaceutical Inc.

Director Daniel Welch reports acquisition of Ultragenyx stock and options, signaling changes in beneficial ownership.

Director Corazon (Corsee) D. Sanders of Ultragenyx Pharmaceutical Inc. reports acquisition of common stock and stock options.

Director Michael Narachi acquired shares and options in Ultragenyx Pharmaceutical Inc. on May 15, 2025, according to a Form 4 filing.

Director Matthew K. Fust reports acquisition of Ultragenyx Pharmaceutical Inc. stock and options.

Director Deborah Dunsire reports acquisition of Ultragenyx Pharmaceutical Inc. shares and stock options.

Director Amrit Ray reports the acquisition of restricted stock units and stock options in Ultragenyx Pharmaceutical Inc.

Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., reported selling shares of common stock to cover tax obligations and participating in the employee stock purchase plan.

Ultragenyx Pharmaceutical's CFO, Howard Horn, sold 1,785 shares of common stock on March 6, 2025, to cover tax withholdings related to vesting RSUs.

Thomas Kassberg, CBO & EVP of Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of company stock related to performance stock units and tax withholdings.

EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., Karah Parschauer, reports acquisition and disposal of company stock related to performance stock units and tax obligations.

Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of common stock and stock options.

John Richard Pinion, an officer at Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of company stock and derivative securities.

Ultragenyx Pharmaceutical Inc. CEO Emil Kakkis reports acquisition and disposal of company stock and derivative securities.

EVP & Chief Commercial Officer of Ultragenyx Pharmaceutical Inc., Erik Harris, reports acquisition and disposal of company stock, including vesting of RSUs and sales to cover tax obligations.

Officer Dennis Karl Huang reports acquisition and disposal of Ultragenyx Pharmaceutical Inc. stock and stock options.

Ultragenyx Pharmaceutical's SVP, Chief Accounting Officer Theodore Alan Huizenga, reports acquisition and disposal of company stock and stock options.

Chief Financial Officer Howard Horn reports acquisition of stock and option awards in Ultragenyx Pharmaceutical Inc.

EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., Karah Parschauer, reports stock sales and acquisitions, including restricted stock units and stock options.